What is the first-line treatment for an adult with major depressive disorder without contraindications?

First-Line Treatment for Major Depressive Disorder

The American College of Physicians strongly recommends initiating treatment with either a second-generation antidepressant (SSRI or SNRI) or cognitive behavioral therapy (CBT) as monotherapy for adults with moderate to severe major depressive disorder. 1

Pharmacologic First-Line Options

Preferred SSRIs

• Sertraline, escitalopram, fluoxetine, paroxetine, or citalopram are the recommended first-line SSRIs, with all demonstrating equivalent efficacy (number needed to treat = 7-8 for remission). 1, 2
• Sertraline is FDA-approved for major depressive disorder and has established efficacy in 6-8 week controlled trials. 3
• Escitalopram shows favorable tolerability and once-daily dosing convenience. 4

Alternative First-Line Agents

• Venlafaxine (SNRI) is an acceptable alternative when SSRI therapy is not preferred. 1
• Bupropion should be strongly considered as first-line when cognitive symptoms (difficulty concentrating, mental fog) are prominent, as it is the most effective agent for these symptoms and has the lowest rate of sexual dysfunction among all antidepressants. 2

Cognitive Behavioral Therapy as First-Line

• CBT demonstrates efficacy equivalent to second-generation antidepressants (response rate RR 0.90, remission rate RR 0.98) based on moderate-quality evidence from 5 trials over 8-52 weeks. 5, 1
• CBT has fewer adverse effects and lower relapse rates compared to pharmacotherapy, making it preferable when patient preference, availability, and cost align. 1

Treatment Selection Algorithm

Base your choice on the following hierarchy:

1. Patient preference after discussing efficacy equivalence, adverse effects, and cost 1
2. Symptom profile:
   • Cognitive symptoms (concentration, mental fog) → bupropion first 2
   • Chronic pain comorbidity → SNRI (duloxetine or venlafaxine) 2
   • Sexual dysfunction concerns → bupropion (8% sexual adverse events vs. higher rates with SSRIs) 2
   • Weight gain concerns → bupropion (minimal weight gain vs. SSRIs) 2
3. Age considerations:
   • Older adults (≥65 years) → citalopram, sertraline, venlafaxine, or bupropion preferred; avoid paroxetine and fluoxetine due to anticholinergic effects 2
   • Young adults (18-24 years) → any SSRI acceptable but requires intensive monitoring for suicidality (see below) 4
4. Special populations:
   • Breastfeeding → sertraline or paroxetine (lower breast milk concentrations) 2

Combination Therapy

• Adding CBT to pharmacotherapy does not significantly improve response or remission rates in most trials, though it may improve work-functioning measures of uncertain clinical significance. 5
• Reserve combination therapy for patients with severe work-functioning impairment. 1

Critical Safety Monitoring

Suicidality Risk by Age

• Adults 18-24 years: Increased risk (OR 2.30; absolute risk increase ~0.7%, NNH = 143); requires weekly visits for the first month, then biweekly through week 8, with explicit assessment of suicidal thoughts, plans, and means at each encounter. 4, 2
• Adults 25-64 years: Neutral effect on suicide risk. 2
• Adults ≥65 years: Protective effect (OR 0.06). 2

Behavioral Activation

• Monitor vigilantly for akathisia, motor restlessness, insomnia, impulsivity, or agitation, especially in the first weeks after initiation or dose increases, as these may precipitate suicidal ideation. 4

Dosing and Duration

• Start low and titrate slowly to minimize tolerability issues, particularly in older adults. 2
• Maintain therapeutic dose for 4-8 weeks before declaring treatment failure; maximal benefit typically emerges by week 12. 4
• Continue treatment for at least 4-9 months after achieving remission for a first episode; extend to ≥12 months for recurrent depression. 2

Medications to Avoid

• Never use tricyclic antidepressants as first-line due to higher adverse effect burden, overdose lethality, and lack of superiority over second-generation antidepressants. 1, 2
• Avoid paroxetine in older adults due to highest anticholinergic effects and sexual dysfunction rates among SSRIs. 2
• Do not prescribe antidepressants for mild depression or subsyndromal symptoms without a current moderate-to-severe episode. 2

Common Pitfalls

• Approximately 63% of patients experience at least one adverse effect (most commonly nausea, diarrhea, sexual dysfunction); anticipate and address these proactively. 2
• 38% of patients will not respond within 6-12 weeks; plan for reassessment and potential switching or augmentation strategies. 2
• Do not assume all SSRIs are identical; paroxetine has notably worse anticholinergic and sexual dysfunction profiles. 2